VALN Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -150.82% compared to Valneva SE's net margin of --. Valneva SE's return on equity of -56.21% beat DBV Technologies SA's return on equity of -280.59%.

Valneva SE has a consensus price target of $12.71, signalling upside risk potential of 36.25%. On the other hand DBV Technologies SA has an analysts' consensus of $40.29 which suggests that it could grow by 87.72%. Given that DBV Technologies SA has higher upside potential than Valneva SE, analysts believe DBV Technologies SA is more attractive than Valneva SE.

Valneva SE has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.

Valneva SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Valneva SE pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Valneva SE quarterly revenues are $34.4M, which are larger than DBV Technologies SA quarterly revenues of --. Valneva SE's net income of -$51.8M is lower than DBV Technologies SA's net income of -$33M. Notably, Valneva SE's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Valneva SE is 3.89x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -150.82% compared to Valneva SE's net margin of --. Valneva SE's return on equity of -56.21% beat Innate Pharma SA's return on equity of -72.79%.

Valneva SE has a consensus price target of $12.71, signalling upside risk potential of 36.25%. On the other hand Innate Pharma SA has an analysts' consensus of $5.75 which suggests that it could grow by 232.37%. Given that Innate Pharma SA has higher upside potential than Valneva SE, analysts believe Innate Pharma SA is more attractive than Valneva SE.

Valneva SE has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.017, suggesting its less volatile than the S&P 500 by 101.669%.

Valneva SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Valneva SE pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Valneva SE quarterly revenues are $34.4M, which are larger than Innate Pharma SA quarterly revenues of --. Valneva SE's net income of -$51.8M is higher than Innate Pharma SA's net income of --. Notably, Valneva SE's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Valneva SE is 3.89x versus 22.34x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -150.82% compared to Valneva SE's net margin of --. Valneva SE's return on equity of -56.21% beat Inventiva SA's return on equity of --.

Valneva SE has a consensus price target of $12.71, signalling upside risk potential of 36.25%. On the other hand Inventiva SA has an analysts' consensus of $15.48 which suggests that it could grow by 166.96%. Given that Inventiva SA has higher upside potential than Valneva SE, analysts believe Inventiva SA is more attractive than Valneva SE.

Valneva SE has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28%.

Valneva SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Valneva SE pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Valneva SE quarterly revenues are $34.4M, which are larger than Inventiva SA quarterly revenues of --. Valneva SE's net income of -$51.8M is higher than Inventiva SA's net income of --. Notably, Valneva SE's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Valneva SE is 3.89x versus 33.77x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Nanobiotix SA has a net margin of -150.82% compared to Valneva SE's net margin of --. Valneva SE's return on equity of -56.21% beat Nanobiotix SA's return on equity of --.

Valneva SE has a consensus price target of $12.71, signalling upside risk potential of 36.25%. On the other hand Nanobiotix SA has an analysts' consensus of $23.61 which suggests that it could grow by 12.27%. Given that Valneva SE has higher upside potential than Nanobiotix SA, analysts believe Valneva SE is more attractive than Nanobiotix SA.

Valneva SE has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.700, suggesting its less volatile than the S&P 500 by 30.038%.

Valneva SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Valneva SE pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.

Valneva SE quarterly revenues are $34.4M, which are larger than Nanobiotix SA quarterly revenues of --. Valneva SE's net income of -$51.8M is higher than Nanobiotix SA's net income of --. Notably, Valneva SE's price-to-earnings ratio is -- while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Valneva SE is 3.89x versus 29.34x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.